BioCentury | Jun 24, 2010
Distillery Therapeutics

Indication: Autoimmune disease

...treat cancer. SciBX 3(25); doi:10.1038/scibx.2010.758 Published online June 24, 2010 Patent and licensing status undisclosed Carrington...
BioCentury | Oct 12, 2009
Company News

DelSite, Nanotherapeutics deal

...Nanotherapeutics acquired DelSite's GelVac drug delivery assets in a Chapter 7 bankruptcy sale for $50,000. Nanotherapeutics...
...in a Chapter 7 bankruptcy sale for $50,000. Nanotherapeutics gains the GelSite delivery polymer and DelSite's...
...the deal will complement its drug delivery programs. DelSite filed for Chapter 7 in April. DelSite Inc....
BioCentury | Dec 22, 2008
Company News

DelSite board of directors update

DelSite Inc. (OTCBB:DSII), Irving, Texas Business: Dermatology, Infectious, Drug delivery Resigned: George DeMott as chairman, effective May 2009 WIR Staff...
BioCentury | Dec 22, 2008
Company News

DelSite management update

DelSite Inc. (OTCBB:DSII), Irving, Texas Business: Dermatology, Infectious, Drug delivery Retiring: Carlton Turner as president and CEO on Dec. 31; he will become chairman, and CFO Robert Schnitzius will serve as acting president and CEO...
BioCentury | Aug 4, 2008
Company News

DelSite, Medline Industries Inc. deal

...Carrington’s wound and skin care products under a 2000 deal (see BioCentury, Nov. 13, 2000). DelSite...
...start a Phase I trial of its H5N1 avian influenza nasal powder vaccine next quarter. DelSite Inc....
BioCentury | May 26, 2008
Company News

Carrington, National Institutes of Health deal

...Carrington’s DelSite Biotechnologies Inc. subsidiary extended a license to evaluate NIH’s polysaccharide technology’s ability to create...
...vaccine with DelSite’s GelSite delivery polymer. Terms were not disclosed (see BioCentury, May 21, 2007). Carrington...
BioCentury | Jan 21, 2008
Clinical News

GelVac avian H5N1 influenza vaccine: Phase I start

...This year, Carrington’s DelSite Biotechnologies Inc. unit will begin a dose-escalation, U.S. Phase I trial in...
...DelSite Biotechnologies Inc. unit will begin a dose-escalation, U.S. Phase I trial in healthy volunteers. Carrington...
BioCentury | Jan 21, 2008
Clinical News

Carrington preclinical data

...In rabbit and rat models of bird flu, Carrington's avian H5N1 influenza vaccine was safe and...
...vaccine delivered using the GelVac nasal powder delivery system is expected to begin this year. Carrington...
BioCentury | Dec 10, 2007
Company News

Carrington, ImmuneRegen deal

...IRBO and CARN's DelSite Biotechnologies Inc. subsidiary will use DelSite's GelSite polysaccharide polymer to develop a...
...P, is in preclinical testing for multiple indications, including influenza. Financial details were not disclosed. Carrington...
BioCentury | Oct 1, 2007
Company News

Carrington, ElSohly Laboratories Inc. deal

...CARN's DelSite Biotechnologies Inc. subsidiary and ElSohly amended a 2007 deal to increase the number of...
...ElSohly amended a 2007 deal to increase the number of compounds ElSohly can combine with DelSite's...
...delivery technology. ElSohly is developing compounds to treat cancer and performs drug abuse testing services. Carrington...
Items per page:
1 - 10 of 84
BioCentury | Jun 24, 2010
Distillery Therapeutics

Indication: Autoimmune disease

...treat cancer. SciBX 3(25); doi:10.1038/scibx.2010.758 Published online June 24, 2010 Patent and licensing status undisclosed Carrington...
BioCentury | Oct 12, 2009
Company News

DelSite, Nanotherapeutics deal

...Nanotherapeutics acquired DelSite's GelVac drug delivery assets in a Chapter 7 bankruptcy sale for $50,000. Nanotherapeutics...
...in a Chapter 7 bankruptcy sale for $50,000. Nanotherapeutics gains the GelSite delivery polymer and DelSite's...
...the deal will complement its drug delivery programs. DelSite filed for Chapter 7 in April. DelSite Inc....
BioCentury | Dec 22, 2008
Company News

DelSite board of directors update

DelSite Inc. (OTCBB:DSII), Irving, Texas Business: Dermatology, Infectious, Drug delivery Resigned: George DeMott as chairman, effective May 2009 WIR Staff...
BioCentury | Dec 22, 2008
Company News

DelSite management update

DelSite Inc. (OTCBB:DSII), Irving, Texas Business: Dermatology, Infectious, Drug delivery Retiring: Carlton Turner as president and CEO on Dec. 31; he will become chairman, and CFO Robert Schnitzius will serve as acting president and CEO...
BioCentury | Aug 4, 2008
Company News

DelSite, Medline Industries Inc. deal

...Carrington’s wound and skin care products under a 2000 deal (see BioCentury, Nov. 13, 2000). DelSite...
...start a Phase I trial of its H5N1 avian influenza nasal powder vaccine next quarter. DelSite Inc....
BioCentury | May 26, 2008
Company News

Carrington, National Institutes of Health deal

...Carrington’s DelSite Biotechnologies Inc. subsidiary extended a license to evaluate NIH’s polysaccharide technology’s ability to create...
...vaccine with DelSite’s GelSite delivery polymer. Terms were not disclosed (see BioCentury, May 21, 2007). Carrington...
BioCentury | Jan 21, 2008
Clinical News

GelVac avian H5N1 influenza vaccine: Phase I start

...This year, Carrington’s DelSite Biotechnologies Inc. unit will begin a dose-escalation, U.S. Phase I trial in...
...DelSite Biotechnologies Inc. unit will begin a dose-escalation, U.S. Phase I trial in healthy volunteers. Carrington...
BioCentury | Jan 21, 2008
Clinical News

Carrington preclinical data

...In rabbit and rat models of bird flu, Carrington's avian H5N1 influenza vaccine was safe and...
...vaccine delivered using the GelVac nasal powder delivery system is expected to begin this year. Carrington...
BioCentury | Dec 10, 2007
Company News

Carrington, ImmuneRegen deal

...IRBO and CARN's DelSite Biotechnologies Inc. subsidiary will use DelSite's GelSite polysaccharide polymer to develop a...
...P, is in preclinical testing for multiple indications, including influenza. Financial details were not disclosed. Carrington...
BioCentury | Oct 1, 2007
Company News

Carrington, ElSohly Laboratories Inc. deal

...CARN's DelSite Biotechnologies Inc. subsidiary and ElSohly amended a 2007 deal to increase the number of...
...ElSohly amended a 2007 deal to increase the number of compounds ElSohly can combine with DelSite's...
...delivery technology. ElSohly is developing compounds to treat cancer and performs drug abuse testing services. Carrington...
Items per page:
1 - 10 of 84